In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment

International Journal of Cancer

Volumn 100, Issue 1, 2002, Pages 101-110

  Naundorf, Stefanie ^a   Preithner, Susanne ^a   Mayer, Petra ^a   Lippold, Sandra ^a   Wolf, Andreas ^a   Hanakam, Frank ^a   Fichtner, Iduna ^c   Kufer, Peter ^a,b   Raum, Tobias ^a,b   Riethmüller, Gert ^b   Baeuerle, Patrick A ^a   Dreier, Torsten ^a  

^a MICROMET AG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Experimentelle Pharmakologie und Onkologie Berlin Buch GmbH   (Germany)

Author keywords

Edrecolomab; Ep CAM; Monoclonal antibody

Indexed keywords

ADECATUMUMAB; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; EDRECOLOMAB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOMA; COLON CARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; EFFECTOR CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TREATMENT PLANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CHO CELLS; COLONIC NEOPLASMS; COMPLEMENT SYSTEM PROTEINS; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036643516     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10443     Document Type: Article

References (44)

1. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
2. Rituximab as first-line systemic treatment for patients with low-grade lymphoma
3. Clinical trials of antibody therapy
4. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
5. Phase-1 clinical trial of monoclonal antibody in treatment of gastrointestinal tumours
6. Monoclonal antibodies in cancer therapy. New perspectives after the colorectal carcinoma trial
7. Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein
8. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2
9. The structural analysis of adhesion mediated by Ep-CAM
10. The biology of the 17-1A antigen (Ep-CAM)
11. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
12. Monoclonal antibody therapy for resected Dukes C colorectal cancer: Seven-year outcome of a multicenter randomized trial
13. Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: Results from a phase III study
14. Oligomeric state of the colon carcinoma-associated glycoprotein GA 733-2 (Ep-CAM/EGP40) and its role in GA 733-mediated homotypic cell-cell adhesion
15. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: A new model to study carcinoma-directed immunotherapy
16. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
17. Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia
18. Ep-CAM overexpression in breast cancer as a predictor of survival
19. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targeting tumours in the upper aerodigestive and respiratory tract
20. A phase 1 trial of the humanized anti-EGP40 monoclonal antibody 3622W94
21. A phase I trial of humanized monoclonal antibody 3622W94 including pharmacokinetics (PK) and immunogenicity evaluation
22. Phase I trial testing multiple doses of humanized monoclonal antibody (Mab) 3622W94
23. Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non small cell lung carcinoma
24. Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions
25. Anti-self antibodies selected from a human IgD heavy chain repertoire: A novel approach to generate therapeutic human antibodies against tumor associated antigens
26. Determination of affinities of murine and chimeric anti α/β T-cell receptor antibodies by flow cytometry
27. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
28. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency
29. Frequent expression of complement resistance factors CD46, CD55 and CD59 on gastrointestinal cencer cells limits the therapeutic potential of monoclonal antibody 17-1A
30. A new microcellular cytotoxicity test based on calcein AM release
31. Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen
32. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
33. The epidermal growth factor receptor in breast cancer
34. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia
35. Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: A potential immunotherapeutic target?
36. The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung
37. The epithelial cellular adhesion molecule (Ep-CAM) is a ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR)
38. Down-regulation of the erbB-2 receptor (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2
39. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and immunotoxin
40. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies
41. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice
42. Ga733/Ep-CAM as a target for passive and active immunotherapy in patients with colorectal carcinoma
43. Humoral anti-diotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A